Orasure Technologies, Inc. · NASDAQ:OSUR

Orasure Technologies — Corporate Update (August 2020)

6 slides from Orasure Technologies's corporate update, Aug 25, 2020

  1. Slide 1: OraSure Technologies Summary of Recent COVID-19 Communications

    OraSure Technologies Summary of Recent CoVID-19 Communications August 25, 2020 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements Disclaimer

    Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause act

  3. Slide 3: Three Distinct COVID-19 Opportunities: Current Progress

    Three Distinct COVID-19 Opportunities: Current Progress+ OraQuick Coronavirus Rapid Antigen Self-test Would use a nasal sample easily collected from the lower nostril to maximize accuracy and convenience Currently in clinical testing with human subjects Expected launch in Q4 2020 following EUA Initi

  4. Slide 4: OraQuick Coronavirus Rapid Antigen Self-Test: Three Parallel Pathways to Launch

    OraQuick Coronavirus Rapid Antigen Self-Test: Three Parallel Pathways to Launch Phased approach to EUA To bring the product to market as quickly as possible Clinical Trial Pathway Rapid antigen self-test is currently in human clinical testing This will provide the necessary, real-use data to file fo

  5. Slide 5: Expansion of Manufacturing Capacity to Meet Anticipated Demand for COVID-19 Opportunities

    Expansion of Manufacturing Capacity to Meet Anticipated Demand for COVID-19 Opportunities Current capacity for 35 million OraQuick test per year including HIV, HCV and Ebola tests+ Installation of new lines will expand total capacity for all tests to 55 million tests per year Further expansion will

  6. Slide 6: All-in-one, easy, reliable and non-invasive self-collection

    All-in-one, easy, reliable and non-invasive self-collection High quality DNA and RNA Ambient temperature stability Compatible with high throughput processing Four customers to date* have received EUAs incorporating our sample collection products with more expected to follow All-in-one solutions for

OraSure Technologies — Corporate Update (August 2020) on 6ix